about the author

Kyle Blankenship

kyle@endpointsnews.com @ka_blankenship
Kyle Blankenship on LinkedIn

author articles

Gene ther­a­pies in the knee? With the help of a small herd of hors­es, a new start­up hopes to crack os­teoarthri­tis

5 years ago
Startups
Cell/Gene Tx

Re­searchers are look­ing to solve PTSD. Could MD­MA-as­sist­ed ther­a­pies pro­vide an an­swer?

5 years ago
R&D

Can a top­i­cal treat­ment beat block­buster eye in­jecta­bles? A Swiss biotech has the cash now to find out

5 years ago
Financing

Avro­bio re­tools Fab­ry gene ther­a­py plans af­ter com­pet­ing drug's full ap­proval shuts path­way to an ac­cel­er­at­ed nod

5 years ago
Cell/Gene Tx

J&J bids for EU OK on Leg­end CAR-T; FDA ex­tends re­view pe­ri­od for Arde­lyx's phos­pho­rus con­trol drug

5 years ago
News Briefing

Bob­bing on a sea of crises, blue­bird's Nick Leschly sees his pay cut in half as the biotech pre­pares to split

5 years ago
People
Pharma

Stan­ley Er­ck bagged $48M in pay as he guid­ed No­vavax on a re­mark­able turn­around in the hunt for a Covid-19 vac­cine

5 years ago
People
Coronavirus

Star­ing at a down quar­ter for Op­di­vo, Bris­tol My­ers keeps its eyes on price com­pe­ti­tion po­ten­tial in packed PD-1 ...

5 years ago
Pharma

The biotech craze hits the Nordics, dri­ving a record-high $62M Se­ries A for a Copen­hagen-based ADC play­er

5 years ago
Financing

What caused Roche's Hunt­ing­ton's drug tomin­ersen to hit the skids in late-stage test? It's com­pli­cat­ed, an­a­lysts say

5 years ago
R&D

Bio­gen's Michel Vounatsos takes home $18.7M in pay as the com­pa­ny bat­tles to take ad­u­canum­ab to mar­ket

5 years ago
People
Pharma

Re­gen­eron's Len Schleifer, George Yan­copou­los start their am­bi­tious 5-year plan, earn­ing a front-loaded $270M ...

5 years ago
People
Pharma

UniQure gets an­oth­er shot with he­mo­phil­ia gene ther­a­py af­ter FDA lifts clin­i­cal hold; Ne­oleuk­in's IL-2 hope­ful al­so ...

5 years ago
Cell/Gene Tx
FDA+

J&J's Trem­fya scores 5-year pso­ri­a­sis win in AAD da­ta dump; Roche, Re­gen­eron drugs among lat­est to earn EU ad­vi­so­ry ...

5 years ago
News Briefing

Bris­tol My­er­s' next-gen im­munol­o­gy med busts Am­gen's Ote­zla in head-to-head study. Is a show­down com­ing?

5 years ago
R&D

With 7 PD-(L)1s on the mar­ket, price com­pe­ti­tion has­n't been a fac­tor. Will Re­gen­eron be the first to ask for less?

5 years ago
Pharma

Evotec strength­ens its French con­nec­tion, pledg­ing to drop $120M in­to Toulouse plant for Covid-19 an­ti­bod­ies

5 years ago
Outsourcing
Manufacturing

Ear­ly Zymer­gen in­vestor Jen­ny Rooke re­flects on 'chimeras' in biotech, what it takes to spot a $500M gem

5 years ago
People
Financing

Zymer­gen's bid to dis­rupt a $3T in­dus­tri­al man­u­fac­tur­ing mar­ket goes vi­ral, earn­ing a mas­sive $500M IPO

5 years ago
Financing
Manufacturing

An EU biotech looks to rewrite the ug­ly his­to­ry of phos­phatases, and it's tak­ing $24M in fund­ing to get off the ...

5 years ago
Financing

Ex­clu­sive: Genen­tech's for­mer Tecen­triq 'CEO' jumps ship to head up com­mer­cial at an on­colyt­ic virus play­er

5 years ago
People

Saman­tha Du's Zai Lab sets its am­bi­tions sky high, look­ing to raise $750M to fu­el its li­cens­ing busi­ness mod­el

5 years ago
Financing

The doc­tor is in: Trump in­sid­er Ben Car­son joins NASH play­er Galectin as a 'spe­cial con­sul­tant,' part-time spokesman

5 years ago
People

Till­man Gern­gross' Covid-19 an­ti­body moon­shot scores $336M with the help of new ace CFO. Is an IPO next?

5 years ago
Financing
Coronavirus
First page Previous page 11121314151617 Next page Last page
A service from the Financial Times